International Journal of Cancer · 2013 · 284 citations · 41 references
MedicineOncologyPharmacologyCancer ImmunologyChemotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCytotoxic ChemotherapyCytotoxic T Lymphocyte ResponsesImmunogenic Cell DeathT Cell Responses To TumorsAntitumor Immune ActivationCell Death In CancerChemotherapy-induced ApoptosisChemotherapy-induced Immunogenic Cell DeathDendritic Cell-t Cell InteractionImmunogenic Cell Death InductionT Cell CytotoxicityT Cell-mediated Tumor Killing
Certain chemotherapeutic regimens trigger cancer cell death while inducing dendritic cell maturation and subsequent immune responses. However, chemotherapy-induced immunogenic cell death (ICD) has thus far been restricted to select agents. In contrast, several chemotherapeutic drugs modulate antitumor immune responses, despite not inducing classic ICD. In addition, in many cases tumor cells do not die after treatment. Here, using docetaxel, one of the most widely used cancer chemotherapeutic agents, as a model, we examined phenotypic and functional consequences of tumor cells that do not die from ICD. Docetaxel treatment of tumor cells did not induce ATP or high-mobility group box 1 (HMGB1) secretion, or cell death. However, calreticulin (CRT) exposure was observed in all cell lines examined after chemotherapy treatment. Killing by carcinoembryonic antigen (CEA), MUC-1, or PSA-specific CD8(+) CTLs was significantly enhanced after docetaxel treatment. This killing was associated with increases in components of antigen-processing machinery, and mediated largely by CRT membrane translocation, as determined by functional knockdown of CRT, PERK, or CRT-blocking peptide. A docetaxel-resistant cell line was selected (MDR-1(+), CD133(+)) by continuous exposure to docetaxel. These cells, while resistant to direct cytostatic effects of docetaxel, were not resistant to the chemomodulatory effects that resulted in enhancement of CTL killing. Here, we provide an operational definition of "immunogenic modulation," where exposure of tumor cells to nonlethal/sublethal doses of chemotherapy alters tumor phenotype to render the tumor more sensitive to CTL killing. These observations are distinct and complementary to ICD and highlight a mechanism whereby chemotherapy can be used in combination with immunotherapy.
41
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Noëlia Casares, Marie O. Péquignot, Antoine Tesnière et al. · The Journal of Experimental Medicine · 2005 · 1.5K citations · Full text
Medicine, Immunology, Oncology +17
Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death
Theocharis Panaretakis, Oliver Kepp, Ulf Brockmeier et al. · The EMBO Journal · 2009 · 826 citations · Full text